Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldesleukin + rituximab
- Development stage
- Unknown
- Lead developer
- Clinigen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
Aldesleukin + rituximab is a combination regimen of recombinant human interleukin‑2 (aldesleukin) with the anti‑CD20 monoclonal antibody rituximab, investigated to enhance antibody‑dependent cellular cytotoxicity against B‑cell malignancies by expanding and activating Fc receptor–bearing effector cells such as NK cells. Clinical studies in relapsed/refractory low‑grade non‑Hodgkin lymphoma tested subcutaneous low‑dose aldesleukin alongside standard intravenous rituximab; while aldesleukin increased circulating CD8+/CD56+ cells and augmented ADCC, objective response rates in rituximab‑refractory patients were low, indicating limited clinical benefit in that setting.[3][1]
- Brand names
- ProleukinRituxanRuxienceTruximaRiabni
- Other names
- IL-2 + rituximabinterleukin-2 + rituximabProleukin + rituximab
02
Targets
CD20 (B-lymphocyte antigen CD20)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on aldesleukin + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldesleukin + rituximab.